Moleculin Biotech (MBRX)

• Market cap: $14.6M
• 1 day: 3.92%
• 5 days: -1.85%
• 1 month: 8.87%
• 3 months: -31.17%
• 6 months: -58.27%
• Year to date: -40.11%
• 1 year: -78.88%
• 5 years: -98.92%
• 10 years: -99.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Employees: 17

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

11% more funds holding

Funds holding: 18 [Q3] → 20 (+2) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

1.59% less ownership

Funds ownership: 16.16% [Q3] → 14.57% (-1.59%) [Q4]

40% less capital invested

Capital invested by funds: $1.31M [Q3] → $790K (-$518K) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 277% upside
• Avg. target: $6 466% upside
• High target: $8 655% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Jason McCarthy 16% 1-year accuracy 5 / 32 met price target	277% upside $4	Buy Upgraded	25 Mar 2025
HC Wainwright & Co. Vernon Bernardino 27% 1-year accuracy 19 / 70 met price target	655% upside $8	Buy Reiterated	25 Mar 2025